Capsule Summaries

Share

Program Content

Activities

  • SAVANNAH
    SAVANNAH: Phase II Trial of Savolitinib + Osimertinib for Advanced EGFRm NSCLC With MET Amplification or Overexpression After Progressing on Osimertinib
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 02, 2025

    Expires: October 01, 2025

  • LAURA Updated OS
    LAURA: Updated Overall Survival for Phase III Trial of Osimertinib vs Placebo After Definitive Chemoradiotherapy for Unresectable Stage III EGFR-Mutated NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 09, 2025

    Expires: October 08, 2025

  • SOHO 01
    SOHO-01: Phase I/II Study of BAY 2927088 for Previously Treated HER2-Mutant NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 09, 2025

    Expires: October 08, 2025

  • EMPOWER Lung 1
    EMPOWER-Lung 1: Cemiplimab Continuation Plus Chemotherapy After Progression on 1L Cemiplimab Monotherapy in Advanced NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 10, 2025

    Expires: October 09, 2025

  • MARIPOSA
    MARIPOSA: Final Overall Survival of First-line Amivantamab + Lazertinib vs Osimertinib for Untreated EGFRm Advanced NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 10, 2025

    Expires: October 09, 2025

  • ORCHARD
    ORCHARD: Phase II Study of Osimertinib + Datopotamab Deruxtecan in Advanced EGFRm NSCLC After 1L Osimertinib
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 10, 2025

    Expires: October 09, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc